Tapping the genome's social network to find cancer drivers

December 5, 2017 by Tom Ulrich
Tapping the genome's social network to find cancer drivers
Credit : Lauren Solomon, Broad Communications (adapted from Horn H, Lawrence MS, et al.)

Any one tumor might harbor mutations in thousands of different genes. The challenge is to find the driver mutations—which fuel cancerous activity, and might be promising treatment targets—within the haystack of passengers (mutations that, while present in the tumor, do not help it grow or spread).

In a paper in Nature Methods, a team led by Heiko Horn and Kasper Lage of the Broad Institute's Stanley Center for Psychiatric Research and Massachusetts General Hospital MGH; Michael Lawrence and Jesse Boehm of the Broad Cancer Program; and Gad Getz of the Cancer Program and MGH describe NetSig, an open-source computational tool that looks for cancer-driving mutations by joining cancer genome data with protein interaction data. NetSig is designed to complement existing tools and expand discovery from cancer genomes in any existing analysis pipeline.

Proteins interactions reveal a sort of genomic Facebook, a social network through which genes share information and carry out a cell's functions. The added functional perspective can help researchers identify with greater confidence, especially in genes that mutate only rarely.

To that end, NetSig taps InWeb_InBioMap (InWeb_IM), a protein interaction map with data on more than half a million protein-protein interactions. Lage's lab developed InWeb_IM in 2016 for functionally interpreting large genomic data sets.  

To develop NetSig, the team merged InWeb_IM with The Cancer Genome Atlas (TCGA)-derived exome data from 4,742 tumors spanning 21 cancer types. The team then tested the tool's capabilities in a series of in silico and in vivo experiments, finding that NetSig could:

  1. Recognize known cancer drivers in 60 percent of tested tumor types, including those with relatively few samples.
  2. Predict new driver genes that validation experiments—conducted with the Cancer Program's Target Accelerator initiative—showed were truly tumor-promoting.
  3. Identify hitherto-unnoticed drivers lurking in TCGA and other datasets. In particular, NetSig revealed that between 4 and 14 percent of lung patients previously deemed oncogene-negative (that is, had no detectable oncogenes present) may actually harbor -promoting extra copies of the AKT2 or TFDP2.

Explore further: Shifting protein networks in breast cancer may alter gene function

More information: Heiko Horn et al. NetSig: network-based discovery from cancer genomes, Nature Methods (2017). DOI: 10.1038/nmeth.4514

Taibo Li et al. A scored human protein–protein interaction network to catalyze genomic interpretation, Nature Methods (2016). DOI: 10.1038/nmeth.4083

Related Stories

Shifting protein networks in breast cancer may alter gene function

November 30, 2017
A given gene may perform a different function in breast cancer cells than in healthy cells due to changes in networks of interacting proteins, according to a new study published in PLOS Computational Biology.

Largest resource of human protein-protein interactions can help interpret genomic data

November 28, 2016
An international research team has developed the largest database of protein-to-protein interaction networks, a resource that can illuminate how numerous disease-associated genes contribute to disease development and progression. ...

Mutant gene network in colon cancer identified

November 10, 2017
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this ...

Searching for the 'signature' causes of BRCAness in breast cancer

August 21, 2017
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature (a pattern of base swaps—e.g., Ts for Gs, Cs for As—throughout a genome) known in cancer genomics as "Signature ...

'Big Data' used to identify new cancer driver genes

October 20, 2015
In a collaborative study led by Sanford Burnham Prebys Medical Discovery Institute (SBP), researchers have combined two publicly available 'omics' databases to create a new catalogue of 'cancer drivers'. Cancer drivers are ...

Recommended for you

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.